Human papillomavirus (HPV) infection causes virtually all cases of cervical cancer, the
second most common cause of death from cancer among women worldwide. This Review …

… An estimated 5% of human cancers are caused by human papillomavirus (HPV) infections,
and most of these cancers are of the cervix. Two prophylactic HPV vaccines that target the …

… for HPV vaccination and mainly focus on prophylactic vaccines and approaches … vaccines
or biosimilars—and discuss alternative production strategies. We also present novel vaccine …

… The discovery of the human papillomavirus (HPV) infection being associated with a variety …
the development of prophylactic HPV vaccines. Currently, four HPV vaccines are available on …

… Clinical trials have shown prophylactic human papillomavirus (HPV) vaccines to be effective
against infection and disease. We examined whether HPV vaccination has the potential to …

… prophylactic vaccines based on papillomavirus L1 virus-like particles (VLPs) are currently in
human … infection because a combined prophylactic/therapeutic vaccine may be expected to …

… Effect of prophylactic human papillomavirus L1 virus-likeparticle vaccine on risk of
cervical intraepithelial neoplasia … Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle …

… This article provides a broad overview of clinical trial results for the two licensed prophylactic
human papillomavirus (HPV) vaccines, Cervarix ® (GlaxoSmithKline Biologicals, Rixensart, …

… infection, on prophylactic HPV vaccines, and on recommendations for use of HPV vaccine
in the US. In addition, we discuss vaccine implementation, including evaluation of safety and …

… This dramatic increase in OPC is driven by human papillomavirus (HPV) infection. … vaccines
on the prevention of OPC. To our knowledge, the 3 available prophylactic HPV vaccines …